Ligand Pharmaceuticals Incorporated (LGND) Q4 FY25 Earnings Call

Royalty growth remains strong, but 2026 earnings growth is moderated by a 2025 one-time license fee [22][32].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-28
Length49 minutes
EPS$2.12
Revenue$115.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26 · Q2 FY25

All LGND earnings · Back to LGND overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.